<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177970</url>
  </required_header>
  <id_info>
    <org_study_id>0311034</org_study_id>
    <nct_id>NCT00177970</nct_id>
  </id_info>
  <brief_title>IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff</brief_title>
  <official_title>Intravenous Immunoglobulin G Versus Placebo for the Treatment of Patients With Severe Clostridium Difficile-Associated Diarrhea and Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shadyside Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, eligible patients will be randomly assigned to receive a single dose of 400
      mg/kg of IVIG or a normal saline infusion as placebo over 4-6 hours, in addition to their
      usual medications for CDAD. We expect to enroll approximately 40 patients over a period of
      two years from UPMC Shadyside Hospital, McKeesport Hospital, and St. Margaret's Hospital who
      are unresponsive to standard antimicrobial therapy for CDAD.

      During the course of this study we expect that IVIG group compared with placebo group will
      have fewer number of stools per day (&lt; 3 per day). Secondary endpoints will include normal
      WBC count, normal body temperature, 75% reduction in abdominal pain / tenderness, and
      decrease in length of hospital stay.

      Subjects will sign a written informed consent prior to any study procedures. Patients will be
      monitored closely during the infusion of the study medication and will continue to be
      monitored on a daily basis up to the time of discharge. Data collection will include vital
      signs, CBC, stool C. difficile cytotoxin assay, and stool counts before and after therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See &quot;Brief Summary&quot; for details
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We were unable to receive IVIG free from phamaceutical company.
  </why_stopped>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1) Normalization of WBC's</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal WBC count 3.8-10.0/CMM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2) Decrease of Number of Loose Stools to &lt;3 Per Day Following Treatment</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will have fewer number of stools per day (&lt;3 per day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) 75% Reduction in Abdominal Pain/Tenderness</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will a 75% reduction in abdominal pain/tenderness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2) Quantity of Anti-C. Difficile Antibodies in Relationship With Recovery of C. Difficile Diarrhea</measure>
    <time_frame>during the course of the study</time_frame>
    <description>The quantity of anti-C. difficile antibodies with improve in relationship with recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) Correlation Between Antibody Responses as Measured With ELISA (Enzyme Immunoassay) and Recovery of C. Difficile Diarrhea</measure>
    <time_frame>during the course of the study</time_frame>
    <description>A correlation will occur between antibody responses as measured with ELISA (enzyme immunoassay) and recovery of C. difficile diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4) Normalization of Neutrophil Count on CBC With Diff.</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will have normalization of neutrophil count (1.6-6.7)on CBC with diff.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5) Normalization of Body Temperature During a 24 Hour Period</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal body temperature of 98.6 F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6) Patients' Length of Hospital Stay</measure>
    <time_frame>during the course of the study</time_frame>
    <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a decrease in length of hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Clostridium Difficile-associated Diarrhea (CDAD)</condition>
  <arm_group>
    <arm_group_label>IVIG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immunoglobulin G (IVIG)</intervention_name>
    <description>IVIG to be given IV to patients with C-Diff .</description>
    <arm_group_label>IVIG</arm_group_label>
    <other_name>IVIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to be given IV to patients with C-Diff</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and female greater than 18 years of age

          2. Positive stool C. difficile cytotoxin assay and/or biopsy evidence of Pseudomembranous
             Colitis (PMC) at onset of illness

          3. Current history of severe, relapsing CDAD or Current history of severe, refractory
             CDAD

          4. A score of 6 or 7 on the C.Diff Severity and Prognosis Score (CDSPS) scale27,28,29,30
             OR failure to respond (as identified by a score of 4 or more on the CDSPS scale below)
             to any of the following: a 4-day or more course of oral or IV metronidazole 500 mg po
             TID or QID; or to a 4-day course of oral vancomycin 125-500 mg po Q6 hours; or to a
             4-day course of vancomycin enemas; or failure to respond to a 4-day course of
             combination therapy of oral vancomycin 125-500 mg po Q6 hours and IV metronidazole
             500mg IV Q8 or Q6 hours and/or vancomycin enemas.

        CDSPS SCALE (each item is scored as one point for a 7 point maximum total)

          1. underlying immunosuppression/chronic medical condition

          2. altered or depressed mental status as defined by medical chart documentation

          3. abdominal pain and/or distention

          4. WBC &gt; 20,000 or &lt; 1,500 and/or bandemia &gt; 10%

          5. hypoalbuminemia (&lt;3 mg/dL)

          6. ascites (clinically or per CT scan findings per medical chart)

          7. abnormal CT scan findings per medical chart -

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Selective IgA deficiency

          3. Hypersensitivity to immune globulin, human albumin, or thimerosal -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George L Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC McKeesport Hospital and SemperCare Hospital of McKeesport, Inc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC St. Margaret Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 15, 2016</results_first_submitted>
  <results_first_submitted_qc>June 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2016</results_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>records not available</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment number retrieved from old IRB database and not from study records and cannot be verified.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IVIG</title>
          <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No results available record destroyed due to age of study. no publications</participants>
                <participants group_id="P2" count="0">No results available record destroyed due to age of study. no publications</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No results available record destroyed due to age of study. no publications</participants>
                <participants group_id="P2" count="0">No results available record destroyed due to age of study. no publications</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No results available record destroyed due to age of study. no publications</population>
      <group_list>
        <group group_id="B1">
          <title>IVIG</title>
          <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>No results available record destroyed due to age of study. no publications</description>
          <units>participants</units>
          <param>Number</param>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1) Normalization of WBC's</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal WBC count 3.8-10.0/CMM</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>1) Normalization of WBC's</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal WBC count 3.8-10.0/CMM</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2) Decrease of Number of Loose Stools to &lt;3 Per Day Following Treatment</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will have fewer number of stools per day (&lt;3 per day).</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>2) Decrease of Number of Loose Stools to &lt;3 Per Day Following Treatment</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will have fewer number of stools per day (&lt;3 per day).</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1) 75% Reduction in Abdominal Pain/Tenderness</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will a 75% reduction in abdominal pain/tenderness</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>1) 75% Reduction in Abdominal Pain/Tenderness</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will a 75% reduction in abdominal pain/tenderness</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2) Quantity of Anti-C. Difficile Antibodies in Relationship With Recovery of C. Difficile Diarrhea</title>
        <description>The quantity of anti-C. difficile antibodies with improve in relationship with recovery</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>2) Quantity of Anti-C. Difficile Antibodies in Relationship With Recovery of C. Difficile Diarrhea</title>
          <description>The quantity of anti-C. difficile antibodies with improve in relationship with recovery</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>3) Correlation Between Antibody Responses as Measured With ELISA (Enzyme Immunoassay) and Recovery of C. Difficile Diarrhea</title>
        <description>A correlation will occur between antibody responses as measured with ELISA (enzyme immunoassay) and recovery of C. difficile diarrhea.</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>3) Correlation Between Antibody Responses as Measured With ELISA (Enzyme Immunoassay) and Recovery of C. Difficile Diarrhea</title>
          <description>A correlation will occur between antibody responses as measured with ELISA (enzyme immunoassay) and recovery of C. difficile diarrhea.</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>4) Normalization of Neutrophil Count on CBC With Diff.</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will have normalization of neutrophil count (1.6-6.7)on CBC with diff.</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>4) Normalization of Neutrophil Count on CBC With Diff.</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will have normalization of neutrophil count (1.6-6.7)on CBC with diff.</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5) Normalization of Body Temperature During a 24 Hour Period</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal body temperature of 98.6 F.</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>5) Normalization of Body Temperature During a 24 Hour Period</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a normal body temperature of 98.6 F.</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6) Patients' Length of Hospital Stay</title>
        <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a decrease in length of hospital stay.</description>
        <time_frame>during the course of the study</time_frame>
        <population>No results available record destroyed due to age of study. no publications</population>
        <group_list>
          <group group_id="O1">
            <title>IVIG</title>
            <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
          </group>
        </group_list>
        <measure>
          <title>6) Patients' Length of Hospital Stay</title>
          <description>During the course of the study, we expect the IVIG group compared to the placebo group will have a decrease in length of hospital stay.</description>
          <population>No results available record destroyed due to age of study. no publications</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No results available. Records were destroyed due to age of study.</desc>
      <group_list>
        <group group_id="E1">
          <title>IVIG</title>
          <description>intravenous immunoglobulin G (IVIG): IVIG to be given IV to patients with C-Diff .</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Placebo to be given IV to patients with C-Diff</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. George Arnold</name_or_title>
      <organization>UPittsburgh</organization>
      <phone>4126212334</phone>
      <email>arnoldgl@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

